955 related articles for article (PubMed ID: 26398542)
1. Posaconazole: Use in the Prophylaxis and Treatment of Fungal Infections.
Clark NM; Grim SA; Lynch JP
Semin Respir Crit Care Med; 2015 Oct; 36(5):767-85. PubMed ID: 26398542
[TBL] [Abstract][Full Text] [Related]
2. Posaconazole: an extended-spectrum triazole antifungal agent.
Schiller DS; Fung HB
Clin Ther; 2007 Sep; 29(9):1862-86. PubMed ID: 18035188
[TBL] [Abstract][Full Text] [Related]
3. Posaconazole: an oral triazole with an extended spectrum of activity.
Rachwalski EJ; Wieczorkiewicz JT; Scheetz MH
Ann Pharmacother; 2008 Oct; 42(10):1429-38. PubMed ID: 18713852
[TBL] [Abstract][Full Text] [Related]
4. Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent.
Nagappan V; Deresinski S
Clin Infect Dis; 2007 Dec; 45(12):1610-7. PubMed ID: 18190324
[TBL] [Abstract][Full Text] [Related]
5. [The latest data on posaconazole].
Paugam A
Med Mal Infect; 2007 Feb; 37(2):71-6. PubMed ID: 17267154
[TBL] [Abstract][Full Text] [Related]
6. Posaconazole: clinical pharmacology and potential for management of fungal infections.
Groll AH; Walsh TJ
Expert Rev Anti Infect Ther; 2005 Aug; 3(4):467-87. PubMed ID: 16107193
[TBL] [Abstract][Full Text] [Related]
7. A multicenter, open-label study of posaconazole oral suspension in the treatment of invasive fungal infections in patients refractory to or intolerant of first-line therapy.
Huang X; Wang F; Chen Y; Liu T; Wang J; Hu J; Jie J; Chen F; Wang S; Shen Z; Yu L; Yu K; Liang Y
Future Microbiol; 2012 Feb; 7(2):201-9. PubMed ID: 22324990
[TBL] [Abstract][Full Text] [Related]
8. Efficacy, safety, and breakthrough infections associated with standard long-term posaconazole antifungal prophylaxis in allogeneic stem cell transplantation recipients.
Winston DJ; Bartoni K; Territo MC; Schiller GJ
Biol Blood Marrow Transplant; 2011 Apr; 17(4):507-15. PubMed ID: 20460163
[TBL] [Abstract][Full Text] [Related]
9. Antifungal prophylaxis with posaconazole vs. fluconazole or itraconazole in pediatric patients with neutropenia.
Döring M; Eikemeier M; Cabanillas Stanchi KM; Hartmann U; Ebinger M; Schwarze CP; Schulz A; Handgretinger R; Müller I
Eur J Clin Microbiol Infect Dis; 2015 Jun; 34(6):1189-200. PubMed ID: 25680318
[TBL] [Abstract][Full Text] [Related]
10. Posaconazole.
Keating GM
Drugs; 2005; 65(11):1553-67; discussion 1568-9. PubMed ID: 16033292
[TBL] [Abstract][Full Text] [Related]
11. Posaconazole: a new oral antifungal agent with an expanded spectrum of activity.
Morris MI
Am J Health Syst Pharm; 2009 Feb; 66(3):225-36. PubMed ID: 19179636
[TBL] [Abstract][Full Text] [Related]
12. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
Sabatelli F; Patel R; Mann PA; Mendrick CA; Norris CC; Hare R; Loebenberg D; Black TA; McNicholas PM
Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
[TBL] [Abstract][Full Text] [Related]
13. Posaconazole: a new broad-spectrum antifungal agent.
Kwon DS; Mylonakis E
Expert Opin Pharmacother; 2007 Jun; 8(8):1167-78. PubMed ID: 17516880
[TBL] [Abstract][Full Text] [Related]
14. Posaconazole: a next-generation triazole antifungal.
Farowski F; Vehreschild JJ; Cornely OA
Future Microbiol; 2007 Jun; 2(3):231-43. PubMed ID: 17661696
[TBL] [Abstract][Full Text] [Related]
15. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance.
Fera MT; La Camera E; De Sarro A
Expert Rev Anti Infect Ther; 2009 Oct; 7(8):981-98. PubMed ID: 19803707
[TBL] [Abstract][Full Text] [Related]
16. Posaconazole.
Bhattacharya M; Rajeshwari K; Dhingra B
J Postgrad Med; 2010; 56(2):163-7. PubMed ID: 20622401
[TBL] [Abstract][Full Text] [Related]
17. Antifungal efficacy and pharmacodynamics of posaconazole in experimental models of invasive fungal infections.
Groll AH; Walsh TJ
Mycoses; 2006; 49 Suppl 1():7-16. PubMed ID: 16961576
[TBL] [Abstract][Full Text] [Related]
18. Posaconazole: a broad-spectrum triazole antifungal.
Torres HA; Hachem RY; Chemaly RF; Kontoyiannis DP; Raad II
Lancet Infect Dis; 2005 Dec; 5(12):775-85. PubMed ID: 16310149
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic/pharmacodynamic profile of posaconazole.
Li Y; Theuretzbacher U; Clancy CJ; Nguyen MH; Derendorf H
Clin Pharmacokinet; 2010 Jun; 49(6):379-96. PubMed ID: 20481649
[TBL] [Abstract][Full Text] [Related]
20. Invasive fungal breakthrough infections, fungal colonization and emergence of resistant strains in high-risk patients receiving antifungal prophylaxis with posaconazole: real-life data from a single-centre institutional retrospective observational study.
Auberger J; Lass-Flörl C; Aigner M; Clausen J; Gastl G; Nachbaur D
J Antimicrob Chemother; 2012 Sep; 67(9):2268-73. PubMed ID: 22653819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]